Development Overview. Nightstar intends to progress the programmes through the necessary pre-clinical, IND/CTA enabling and clinical development phases necessary to achieve regulatory product licensure in the US and EU. The programs are in various stages of pre-clinical development and will require a significant amount of activity to get clinic ready. It is anticipated that a number of IND-enabling activities are ‘pipeline’ activities; synergistic activities applicable to all the programmes, supporting the development through to entry into clinical testing.
Appears in 2 contracts
Sources: Licensing Agreement (Nightstar Therapeutics LTD), Licensing Agreement (Nightstar Therapeutics LTD)